KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Total Debt: 2020-2025

Historic Total Debt for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $20.8 million.

  • Recursion Pharmaceuticals' Total Debt fell 27.53% to $20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.8 million, marking a year-over-year decrease of 27.53%. This contributed to the annual value of $27.4 million for FY2024, which is 2303.42% up from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Total Debt is $20.8 million, which was down 9.27% from $22.9 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' 5-year Total Debt high stood at $31.0 million for Q2 2024, and its period low was $536,000 during Q4 2022.
  • Over the past 3 years, Recursion Pharmaceuticals' median Total Debt value was $20.8 million (recorded in 2025), while the average stood at $14.7 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Total Debt plummeted by 94.45% in 2021, and later soared by 2,586.58% in 2024.
  • Recursion Pharmaceuticals' Total Debt (Quarterly) stood at $633,000 in 2021, then fell by 15.32% to $536,000 in 2022, then skyrocketed by 113.06% to $1.1 million in 2023, then skyrocketed by 2,303.42% to $27.4 million in 2024, then fell by 27.53% to $20.8 million in 2025.
  • Its last three reported values are $20.8 million in Q3 2025, $22.9 million for Q2 2025, and $25.0 million during Q1 2025.